Results 1 to 10 of about 2,162,469 (384)

Cytokine Storm [PDF]

New England Journal of Medicine, 2020
From the Department of Medicine, Division of Translational Medicine and Human Genetics, Center for Cytokine Storm Treatment and Laboratory (D.C.F.), and the Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy (C.H.J ...
Fajgenbaum, David C., June, Carl H.
openaire   +3 more sources

IL-10 inhibits cytokine production by activated macrophages. [PDF]

Journal of Immunology, 1991
IL-10 inhibits the ability of macrophage but not B cell APC to stimulate cytokine synthesis by Th1 T cell clones. In this study we have examined the direct effects of IL-10 on both macrophage cell lines and normal peritoneal macrophages.
David Fiorentino, Albert Zlotnik, Tim R. Mosmann, M Howard, Anne O’Garra   +4 more
openalex   +2 more sources

Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes

Frontiers in Immunology, 2018
Interleukin (IL)-4 and IL-13 are related cytokines that regulate many aspects of allergic inflammation. They play important roles in regulating the responses of lymphocytes, myeloid cells, and non-hematopoietic cells.
Ilkka S. Junttila, Ilkka S. Junttila
doaj   +2 more sources

Smoking in asthma is associated with elevated levels of corticosteroid resistant sputum cytokines—an exploratory study [PDF]

, 2013
<p>Background: Current cigarette smoking is associated with reduced acute responses to corticosteroids and worse clinical outcomes in stable chronic asthma. The mechanism by which current smoking promotes this altered behavior is currently unclear.
A McKay, A Sykes, B Pedersen, Carl de Wet, Charles McSharry, Christopher J. Weir, E Goleva, E Goleva, E Irusen, E Juniper, E Livingston, GJ Zijlstra, GW Chalmers, GW Chalmers, H Kerstjens, J Kam, J St-Laurent, JEM Tomlinson, M Althuis, M Broekema, M Spears, Marco Idzko, Mark Spears, MR Edwards, MR Miller, MR Stämpfli, NC Thomson, Neil C. Thomson, R Chaudhuri, R Chaudhuri, R Crapo, R Meijer, R Sher, Rekha Chaudhuri, S Holgate, SC Lazarus, SE Pedersen, SE Wenzel, WE Naugler, Z Qiu, Z Xing   +40 more
core   +21 more sources

IFN-I inducible miR-3614-5p targets ADAR1 isoforms and fine tunes innate immune activation

Frontiers in Immunology, 2022
Regulation of innate immune responses is essential for maintenance of immune homeostasis and development of an appropriate immunity against microbial infection.
Françoise Vuillier, Françoise Vuillier, Zhi Li, Zhi Li, Iain Black, Iain Black, Melania Cruciani, Melania Cruciani, Erminia Rubino, Erminia Rubino, Frédérique Michel, Frédérique Michel, Sandra Pellegrini, Sandra Pellegrini   +13 more
doaj   +1 more source

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease

Nature Communications, 2022
Idiopathic multicentric Castleman disease (iMCD) is a life-threatening inflammatory disease requiring immediate intervention, for which the recommended first-line therapy is the Interleukin-6 pathway inhibitor siltuximab.
Sheila K. Pierson, Laura Katz, Reece Williams, Melanie Mumau, Michael Gonzalez, Stacy Guzman, Ayelet Rubenstein, Ana B. Oromendia, Philip Beineke, Alexander Fosså, Frits van Rhee, David C. Fajgenbaum   +11 more
doaj   +1 more source

Human Ubiquitin-Specific Peptidase 18 Is Regulated by microRNAs via the 3'Untranslated Region, A Sequence Duplicated in Long Intergenic Non-coding RNA Genes Residing in chr22q11.21

Frontiers in Genetics, 2021
Ubiquitin-specific peptidase 18 (USP18) acts as gatekeeper of type I interferon (IFN) responses by binding to the IFN receptor subunit IFNAR2 and preventing activation of the downstream JAK/STAT pathway.
Erminia Rubino, Erminia Rubino, Melania Cruciani, Nicolas Tchitchek, Nicolas Tchitchek, Anna Le Tortorec, Antoine D. Rolland, Önay Veli, Leslie Vallet, Giulia Gaggi, Frédérique Michel, Nathalie Dejucq-Rainsford, Sandra Pellegrini   +12 more
doaj   +1 more source

Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE

Scientific Reports, 2021
Type I Interferon (IFN) was the very first drug approved for the treatment of Multiple Sclerosis (MS), and is still frequently used as a first line therapy. However, systemic IFN also causes considerable side effects, affecting therapy adherence and dose
Anje Cauwels, Sandra Van Lint, Elke Rogge, Annick Verhee, Bram Van Den Eeckhout, Shengru Pang, Marco Prinz, Niko Kley, Gilles Uzé, Jan Tavernier   +9 more
doaj   +1 more source

Role of FK506-sensitive signals in asthmatic lung inflammation

Frontiers in Immunology, 2022
Asthma is airway inflammatory diseases caused by the activation of group 2 innate lymphoid cells (ILC2s) and type 2 helper T (TH2) cells. Cysteine proteases allergen cause tissue damage to airway epithelial cells and activate ILC2-mediated type 2 airway ...
Chihiro Tomiaki, Kosuke Miyauchi, Sewon Ki, Yoshie Suzuki, Narumi Suzuki, Hiroshi Morimoto, Yohei Mukoyama, Masato Kubo, Masato Kubo   +8 more
doaj   +1 more source

Comparison of the Seven Interleukin-32 Isoforms’ Biological Activities: IL-32θ Possesses the Most Dominant Biological Activity

Frontiers in Immunology, 2022
Cytokines are significantly associated with the homeostasis of immune responses in health and disease. Interleukin-32 (IL-32) is a cytokine originally discovered in natural killer cell transcript 4.
Saerok Shim, Siyoung Lee, Yasmin Hisham, Sinae Kim, Sinae Kim, Tam T. Nguyen, Tam T. Nguyen, Afeisha S. Taitt, Jihyeong Hwang, Hyunjhung Jhun, Ho-Young Park, Youngmin Lee, Su Cheong Yeom, Sang-Yeob Kim, Yong-Gil Kim, Soohyun Kim, Soohyun Kim   +16 more
doaj   +1 more source